Skip Navigation

Journal of Tropical Pediatrics 2004 50(4):219-223; doi:10.1093/tropej/50.4.219
© 2004 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Chandran, S.
Right arrow Articles by Wint, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chandran, S.
Right arrow Articles by Wint, Z.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Use of Magnesium Sulphate in Severe Persistent Pulmonary Hypertension of the Newborn

Suresh ChandranA1,, Md. Enamul HaquebA2, H. T. WickramasinghecA3 and Zaw WintA3

A1 Neonatal Medicine,QCCH, Hammersmith Hospital, London, UK A2 SSB Hospital, Kuala Belait, Brunei Darussalam A3 Department of Paediatrics, RIPAS Hospital, Bandar Seri Begawan, BA1710 Brunei Darussalam

Persistent pulmonary hypertension in the newborn (PPHN) is a neonatal emergency due to the failure to achieve normal cardiopulmonary adaptation following delivery. A clinical trial to assess the efficacy of magnesium sulphate (MgSO4) in the treatment of PPHN was conducted in the tertiary level neonatal intensive care unit of RIPAS Hospital, Brunei Darussalam over a period of 2 years. Twelve newborn babies admitted consecutively to the neonatal intensive care unit with severe hypoxemia due to persistent pulmonary hypertension were included in this trial. A loading dose of 200 mg/kg MgSO4 was given over a period of 20 min, followed by a continuous infusion at the rate of 20–150 mg/kg/h to obtain a serum magnesium level between 3.5 and 5.5 mmol/l. No other vasodilators were used and babies were not hyperventilated. Dopamine was commenced at 5–10 g/kg/min before the loading dose of MgSO4 was given. Mean blood pressure was maintained with short periods of dopamine alone or in combination with dobutamine. Oxygen index (OI) and alveolar-arterial oxygen gradient (A-aDO2) showed significant improvement within 24 h of treatment. In this study, MgSO4 was found to be a safe and effective pulmonary vasodilator.MgSO4 could be used as a first-line vasodilator in developing countries because of its low cost and high efficacy. Parenteral MgSO4 is easy to administer and monitor during treatment. When MgSO4 is used, systemic hypotension can be adequately controlled with ionotropes.

* Correspondence: Dr Suresh Chandran, Special Registrar, Neonatal Medicine, QCCH, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK. E-mail <alackal90{at}hotmail.com>


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Trop PediatrHome page
F. Raimondi, F. Migliaro, L. Capasso, G. Ausanio, M. Bisceglia, P. Giliberti, F. Messina, G. Salvia, and R. Paludetto
Intravenous Magnesium Sulphate vs. Inhaled Nitric Oxide for Moderate, Persistent Pulmonary Hypertension of the Newborn. A Multicentre, Retrospective Study
J Trop Pediatr, June 1, 2008; 54(3): 196 - 199.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.